ArticleTranslational andrology and urology2026
The impact of collagenase clostridium histolyticum (CCH) priming on surgical outcomes in Peyronie's disease: a retrospective cohort study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peyronie's disease (PD) is a connective tissue disorder characterized by fibrous plaque formation within the tunica albuginea, resulting in penile curvature, pain, and sexual dysfunction. Although collagenase clostridium histolyticum (CCH) injections are an established nonsurgical therapy, surgical correction remains the gold standard for men with severe deformity or persistent functional impairment. The influence of prior CCH exposure ("CCH priming") on subsequent need for surgical correction and specific surgical outcomes remains incompletely understood. Our aims were to quantify the proportion of men with PD who underwent tunica albuginea plication after CCH therapy and to compare baseline characteristics and surgical outcomes between patients with and without prior CCH exposure. Methods: We conducted a retrospective analysis of 926 men with PD under institutional review board approval. Patients were categorized by prior CCH treatment and subsequent tunica albuginea plication. Continuous variables were compared using independent t-tests, and categorical variables were analyzed with chi-square or Fisher's exact tests. Statistical significance was defined as P<0.05. Our primary outcomes included the proportion of patients undergoing plication after CCH, preoperative and postoperative curvature, in-hospital complications, 30-day and 90-day complication rates, and revision surgery rates. Results: Of 926 patients, 322 received CCH therapy. Among these, 25 (7.8%) underwent subsequent plication compared with 34 (5.6%) of 604 men without prior CCH. Baseline comorbidities were similar between groups, except for a higher prevalence of testosterone replacement therapy use in the CCH cohort. Preoperative curvature did not differ significantly (56.6° Conclusions: Prior CCH exposure was not associated with statistically significant differences in curvature correction or complication rates following tunica albuginea plication, and revision surgery rates were also not statistically different between groups. Larger studies are warranted to improve statistical power to better evaluate potential differences in revision rates and other surgical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.